ARTICLE | Clinical News

Panobinostat: Final Phase II data

December 13, 2010 8:00 AM UTC

Final data from a single-arm, international, pivotal Phase II trial in 129 patients who previously received an autologous stem cell transplant showed that 40 mg thrice-weekly oral panobinostat produced an ORR of 27%, including 5 complete responses and 30 partial responses. Median duration of response was 6.9 months and median PFS was 10.5 months among responders. Overall median PFS was 6.1 months. Additionally, 82% of patients achieved disease control and 74% of patients experienced tumor reduction at a median follow-up of 9.6 months. Data were presented at the American Society of Hematology meeting in Orlando. ...